Global News

AcelRx restructures, reduces workforce 36%

Monday, March 30, 2015 02:17 PM

AcelRx Pharmaceuticals, a California-based specialty pharma focused on development and commercialization of innovative therapies for the treatment of acute pain, has restructured its work force as part of a plan to reduce operating costs and focus its financial and development resources on working with the FDA to seek marketing approval for Zalviso, as well as to continue the development of ARX-04.

More... »

Quest Diagnostics

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015 02:13 PM

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

More... »

Glenn Kerkhof appointed chairman of the board

Monday, March 30, 2015 11:05 AM

George Clinical, a CRO focused on clinical development in the Asia-Pacific region, has appointed Glenn Kerkhof chairman of its board.

More... »

Why we need more older patients in clinical trials

Monday, March 30, 2015 08:00 AM

As our population ages and medical advances increase life expectancy, drug developers are facing an emerging gap in clinical research: lack of evidence to guide treatment decisions for people over 65.

More... »

Vtesse forms scientific advisory board

Friday, March 27, 2015 01:47 PM

Vtesse, a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, has formed its scientific advisory board (SAB). Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company's lead candidate, VTS-270.

More... »

Parkinson's Biomarker Initiative expands genetic study

Friday, March 27, 2015 01:26 PM

The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with a mutation of the GBA (glucosidase beta acid) gene. Participants will include people with or at increased risk to develop Parkinson's disease. Researchers hope that a greater understanding of the biology and clinical features of these participants will lead to therapies benefiting all Parkinson's patients and ultimately provide strategies to prevent disease onset.

More... »

Mast to develop Vepoloxamer (MST-188) in chronic heart failure

Friday, March 27, 2015 01:15 PM

Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure. Encouraged by recently reported nonclinical results and input from experts in the field, the company expects to begin dosing in a phase II study of vepoloxamer in patients with chronic heart failure in the third quarter of this year.

More... »

Ablynx, Merck extend ion channel research collaboration

Friday, March 27, 2015 11:21 AM

Ablynx, a biopharmaceutical company headquartered in Belgium, has extended its initial two-year research collaboration with Merck to develop and commercialize Nanobody candidates directed toward an undisclosed voltage gated ion channel.

More... »

PPD first to migrate data to the Oracle Health Sciences Cloud

Thursday, March 26, 2015 02:58 PM

PPD is the first company to migrate trials from an on-site installation of Oracle Health Sciences’ Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service—creating a highly available, centralized trial database that lowers costs, simplifies management, improves the accuracy of multi-CRO clinical trial data and accelerates studies.

More... »

Parexel to acquire Quantum Solutions India

Thursday, March 26, 2015 02:56 PM

Parexel International, a Boston-based global CRO, has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a provider of specialized pharmacovigilance services.

More... »



April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs